{"id":"anti-vegf","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT00982657","NCT01112527","NCT01994291","NCT00982267","NCT07421700","NCT04171141","NCT00083889","NCT00454649","NCT00557856","NCT03289533","NCT00094107","NCT00076011","NCT01441388","NCT01175070","NCT01798446","NCT00402415","NCT00312351","NCT01911273","NCT01019798","NCT00321997","NCT01004822","NCT00094094","NCT01999972","NCT03472560","NCT00215670"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"2007","type":"neutral","milestone":"Phase 2 Initiated","description":"Phase 2 trial (Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma) — Kidney Neoplasms"},{"date":"2008","type":"negative","milestone":"Phase 1 Initiated","description":"Phase 1 trial (Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With) — Tumors. Trial terminated early."},{"date":"2008","type":"neutral","milestone":"Phase 3 Initiated","description":"Phase 3 trial (SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Ce) — Carcinoma, Renal Cell"},{"date":"2013","type":"neutral","milestone":"Phase 4 Initiated","description":"Phase 4 trial (Intravitreal Macugen for Ischaemic Diabetic Macular Oedema) — Diabetic Macular Oedema"}],"aiSummary":"Anti-VEGF agents, such as bevacizumab and aflibercept, are being studied in clinical trials for various prostate cancer stages, including adenocarcinoma of the prostate and recurrent prostate cancer. These agents are used to target a specific mechanism, but the exact modality of action is currently unknown.","brandName":"Anti-VEGF","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Monoclonal antibody","drugClass":"Anti-VEGF IV (bevacizumab)","explanation":"In certain eye diseases, the body mistakenly produces excessive amounts of a substance called VEGF (vascular endothelial growth factor). This substance acts like a chemical messenger that signals blood vessels to grow rapidly and abnormally. These new vessels are fragile, leak fluid, and cause scarring and vision loss. Anti-VEGF medications work by intercepting this chemical messenger before it can tell blood vessels to grow, essentially stopping the disease at its source.\n\nWhen anti-VEGF drugs are injected into the eye, they bind to and neutralize VEGF molecules circulating in the eye tissue. By removing this growth signal, the abnormal vessels either shrink or stop growing altogether. This prevents the leakage and inflammation that damage the light-sensitive cells in the retina, the part of the eye responsible for vision. The result is that many patients experience stabilized or improved vision, particularly when treated early.\n\nDifferent anti-VEGF medications work slightly differently—some are monoclonal antibodies that directly grab VEGF molecules, while others are smaller proteins that block VEGF receptors on blood vessel cells. Despite these differences, they all aim to achieve the same goal: reducing the abnormal blood vessel growth and preserving the patient's remaining eyesight.","oneSentence":"Anti-VEGF IV (bevacizumab)","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"anti-vegf","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Gastrointestinal Tumors","phase":"discontinued","trialId":"","patients":null,"diseaseId":"oncology","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00982657","phase":"Phase 2","title":"A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Adv","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":34,"indication":"Solid Tumor","completionDate":"2014-03","primaryEndpoint":"The safety and tolerability of CVX-060 have been established in the first-in-human clinical trial, CVX-060-101."},{"nctId":"NCT01112527","phase":"Phase 2","title":"PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma","status":"Completed","sponsor":"Massachusetts General Hospital","isPivotal":false,"enrollment":58,"indication":"Glioblastoma","completionDate":"2015-09","primaryEndpoint":"There are three arms to this study (A, B and C) The purpose of this research study during Arm A is to see how much of PF-00299804 gets into the brain tumor."},{"nctId":"NCT01994291","phase":"Phase 2","title":"A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Anta","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":199,"indication":"Macular Edema, Diabetic","completionDate":"2015-08","primaryEndpoint":"The study hypothesis under test is that administration of the CCR2/5 antagonist has the potential to be as effective as the current treatment options for subjects with diabetic macular edema."},{"nctId":"NCT00982267","phase":"Phase 1","title":"A Trial Of SU14813 In Patients With Advanced Solid Malignancies","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":77,"indication":"Neoplasms","completionDate":"2008-11","primaryEndpoint":"The purpose of this study is to define the Maximum tolerated dose of SU14813 when administered as single agent in patients with solid tumors."},{"nctId":"NCT07421700","phase":"Phase 1/2","title":"A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Can","status":"Not Yet Recruiting","sponsor":"Pfizer","isPivotal":false,"enrollment":132,"indication":"Urothelial Cancer","completionDate":"2027-12","primaryEndpoint":"This study is being done to learn more about a new medicine called PF-08634404."},{"nctId":"NCT04171141","phase":"Phase 1","title":"Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metas","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":79,"indication":"Gastrointestinal Tumors","completionDate":"2023-11","primaryEndpoint":"A phase 1, open-label, dose escalation and expansion study of PF-07062119 in patients with selected advanced or metastatic gastrointestinal tumors"},{"nctId":"NCT00083889","phase":"Phase 3","title":"SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Ce","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":750,"indication":"Carcinoma, Renal Cell","completionDate":"2008-09","primaryEndpoint":"The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC)."},{"nctId":"NCT00454649","phase":"Phase 1","title":"Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With ","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":102,"indication":"Neoplasms","completionDate":"2009-08","primaryEndpoint":"To determine the best dose of this investigational agent AG-013736 in combination with various standard of care treatments for advanced solid tumors."},{"nctId":"NCT00557856","phase":"Phase 1","title":"A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":70,"indication":"Advanced Solid Tumors","completionDate":"2013-03","primaryEndpoint":"The purpose of this study is to test the safety and effectiveness of PF-03446962 when given as a single agent."},{"nctId":"NCT03289533","phase":"Phase 1","title":"A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":22,"indication":"Carcinoma, Hepatocellular","completionDate":"2019-08","primaryEndpoint":"To evaluate the safety, efficacy and PK of avelumab in combination with axitinib as first line treatment in patients with advanced HCC"},{"nctId":"NCT00094107","phase":"Phase 2","title":"Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":32,"indication":"Melanoma","completionDate":"2008-04","primaryEndpoint":"This is a Phase 2 study being conducted at multiple centers in the United States and France."},{"nctId":"NCT00076011","phase":"Phase 2","title":"Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":52,"indication":"Kidney Neoplasms","completionDate":"2007-02","primaryEndpoint":"The primary purpose of this protocol is to determine the activity of AG 013736 in patients with metastatic renal cell cancer who have received 1 prior cytokine-based therapy."},{"nctId":"NCT01441388","phase":"Phase 1","title":"A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.","status":"Withdrawn","sponsor":"Pfizer","isPivotal":false,"enrollment":0,"indication":"Carcinoma, Renal Cell","completionDate":"2013-11","primaryEndpoint":"Despite the success of anti-angiogenic therapy in multiple treatment settings, a fraction of patients are refractory to vascular endothelial growth factor (VEGF) inhibitor treatment while the majority"},{"nctId":"NCT01175070","phase":"Phase 4","title":"Intravitreal Macugen for Ischaemic Diabetic Macular Oedema","status":"Completed","sponsor":"University of Oxford","isPivotal":false,"enrollment":30,"indication":"Diabetic Macular Oedema","completionDate":"2013-03","primaryEndpoint":"Diabetic macular oedema (DME) is one of the leading causes of blindness in the United Kingdom's working population."},{"nctId":"NCT01798446","phase":"Phase 2","title":"A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously T","status":"Completed","sponsor":"Seoul National University Hospital","isPivotal":false,"enrollment":41,"indication":"Renal Cell Carcinoma","completionDate":"2015-06","primaryEndpoint":"There is no standard treatment option for non-clear cell renal cell carcinoma (RCC)."},{"nctId":"NCT00402415","phase":"Phase 1","title":"Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With","status":"Terminated","sponsor":"Yale University","isPivotal":false,"enrollment":18,"indication":"Tumors","completionDate":"2008-07","primaryEndpoint":"There are two drugs involved in this study."},{"nctId":"NCT00312351","phase":"Phase 4","title":"A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in","status":"Terminated","sponsor":"Eyetech Pharmaceuticals","isPivotal":false,"enrollment":262,"indication":"Macular Degeneration","completionDate":"","primaryEndpoint":"The purpose of this trial is to compare the ability of three different doses of pegaptanib sodium to safely and effectively minimize fluid leakage within the eye, thereby stabilizing or improving visi"},{"nctId":"NCT01911273","phase":"Phase 2","title":"A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal An","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":3,"indication":"Carcinoma, Hepatocellular","completionDate":"2014-07","primaryEndpoint":"The primary purpose of the study is to explore whether treatment with PF-03446962 and best supportive care is better than placebo plus best supportive care in prolonging survival of patients affected "},{"nctId":"NCT01019798","phase":"Phase 2","title":"Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell L","status":"Unknown","sponsor":"Taipei Medical University Hospital","isPivotal":false,"enrollment":16,"indication":"Non Small Cell Lung Cancer","completionDate":"2010-12","primaryEndpoint":"Sunitinib shows anti-tumor activity in a variety of human non-small cell lung tumor ex vivo models."},{"nctId":"NCT00321997","phase":"Phase 2/3","title":"A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to","status":"Completed","sponsor":"Eyetech Pharmaceuticals","isPivotal":false,"enrollment":540,"indication":"Age-Related Macular Degeneration","completionDate":"","primaryEndpoint":"The purpose of this study is to compare the ability of different doses of pegaptanib sodium to safely and effectively minimize fluid leakage within the eye, thereby stabilizing or impriving vision in "},{"nctId":"NCT01004822","phase":"Phase 1","title":"A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumor","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":31,"indication":"Advanced Solid Tumors","completionDate":"2014-05","primaryEndpoint":"The purpose of this study is to determine if CVX-241 (PF-05057459) is safe and tolerable when given as weekly infusions to adult patients with advanced solid tumors."},{"nctId":"NCT00094094","phase":"Phase 2","title":"Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":32,"indication":"Lung Neoplasms","completionDate":"2007-07","primaryEndpoint":"This is a Phase 2 study being conducted at multiple centers in the United States and Germany."},{"nctId":"NCT01999972","phase":"Phase 1","title":"A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":50,"indication":"Advanced Solid Tumors","completionDate":"2017-02","primaryEndpoint":"Despite the success of anti-angiogenic therapy in multiple treatment settings, a fraction of patients are refractory to vascular endothelial growth factor (VEGF) inhibitor treatment, while the majorit"},{"nctId":"NCT03472560","phase":"Phase 2","title":"A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":61,"indication":"Non-Small Cell Lung Cancer","completionDate":"2023-02","primaryEndpoint":"This is a Phase 2 study to evaluate the safety and efficacy of avelumab in combination with axitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have received at lea"},{"nctId":"NCT00215670","phase":"Phase 2/3","title":"Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in","status":"Completed","sponsor":"Eyetech Pharmaceuticals","isPivotal":false,"enrollment":125,"indication":"Age-Related Macular Degeneration","completionDate":"","primaryEndpoint":"The objectives of this study are to characterize the safety, tolerability and pharmacokinetics of pegaptanib when given as 1 or 3mg/eye intravitreous injections every 6 weeks for 54 weeks in patients "}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"crossReferences":{"chemblId":"CHEMBL2108941","pubchemSID":"528618"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Monoclonal antibody","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":17,"withResults":5},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}